Interactions on record — worth a quick check against your medications. Check your meds →
Dietary supplement

Mass Stack Extreme Ingredients & Drug Interactions

by Mass Genetics

Capsule Category: Non-nutrient/non-botanical
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Mass Stack Extreme is a dietary supplement by Mass Genetics with 4 active ingredients. Its ingredients are commonly taken for muscle building, athletic performance, fat loss / body recomposition.Based on those ingredients, 614 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Ostarine, Ligandrol, Arimistane. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Mass Stack Extreme by Mass Genetics

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 4 of its 4 active ingredients.
  • No proprietary blends here — you can verify the dose of every single component.

Mass Stack Extreme contains four active ingredients. Ostarine and ligandrol are selective androgen receptor modulators (SARMs) — experimental drugs designed to affect muscle and bone.

Arimistane is an aromatase inhibitor, a compound believed to affect hormones by blocking an enzyme involved in estrogen production. Laxogenin is a plant steroid.

The product has no inactive ingredients listed.

Does it work?

Not established
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Not established

The graded evidence we hold for these ingredients covers different conditions than the ones this product is marketed for, so there's no established rating for its stated use.

Why this rating?
  • The label markets this product for: intense bulking and strength increase.
  • We looked for evidence on: Athletic performance, Muscle strength, Muscular dystrophy, Sarcopenia, muscle mass, body composition — and 1 related terms.
  • The closest evidence on file: Ostarine is rated "Insufficient Reliable Evidence To Rate" for Athletic performance (Natural Medicines).
  • Also on file: Ostarine is rated "Insufficient Reliable Evidence To Rate" for Muscular dystrophy, Sarcopenia.
  • Also on file: Arimistane is rated "Insufficient Reliable Evidence To Rate" for Athletic performance, Muscle strength.

The evidence for these ingredients is not established in the data we hold. Ostarine, ligandrol, and arimistane all carry ratings of insufficient reliable evidence to rate for athletic performance, muscle strength, cachexia (muscle wasting), and related uses.

Laxogenin has no effectiveness ratings in our data. None of these ingredients have a body of clinical evidence that supports their use for muscle or performance benefits.

The evidence, ingredient by ingredient Ostarine Ligandrol Arimistane Laxogenin

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 2 of the 4 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 4 of 4.
  • General safety write-ups exist for 4 of 4.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

This product carries serious safety warnings. Ostarine and ligandrol are unapproved investigational drugs — they have never been approved by the FDA and carry documented safety risks, including liver injury documented in clinical studies and case reports.

Both can raise liver enzymes and cause abdominal pain, nausea, diarrhea, and constipation. Ligandrol has also been tied to drops in good cholesterol (HDL).

Arimistane is a hormone-altering compound with minimal safety data and regulators warn against aromatase inhibitor supplements. Laxogenin has very limited human safety data and product quality varies widely.

Side effects, ingredient by ingredient Ostarine Ligandrol Arimistane Laxogenin

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 3 of the 4 matched ingredients can interact with medications — Ostarine, Arimistane, Ligandrol.
  • The most serious interaction on file is rated Moderate.
  • For scale: 615 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

If you take any hepatotoxic drugs (those that can harm the liver), drugs metabolized by CYP3A4, probenecid (Benemid) for gout, or aromatase inhibitors for breast cancer or other uses, check with your doctor or pharmacist before taking this product. No interactions are documented for laxogenin, but that does not mean none exist.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with no established evidence rating for its marketed use. Moderate medication interactions have been identified, and safety information is well characterized.

This product contains unapproved investigational drugs with real safety risks and insufficient evidence of benefit. The combination poses a liver safety concern, especially if you take other drugs that stress the liver or are processed by liver enzymes.

Pregnancy and breastfeeding are contraindicated. Before taking this product — and especially if you take any prescription medication or have liver disease — talk it over with your doctor or pharmacist.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 4 of 4 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Jan 25, 2020.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Mass Stack Extreme, straight from the product label.

Brand Mass Genetics
Net contents 60 Cap(s)
Market status On market
Date entered into DSLD Jan 25, 2020
DSLD ID 211457
Product type Non-nutrient/non-botanical
Supplement form Capsule
Dietary claims / uses All Other
Intended target group(s) Adult (18 - 50 Years)
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Mass Stack Extreme by Mass Genetics, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
2 Capsule(s)
Maximum serving Sizes:
2 Capsule(s)
Servings per container
30
IngredientAmount% DV
Ostarine60 mg--
Ligandrol30 mg--
Arimistane30 mg--
Laxogenin50 mg--

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formulation

Intense bulking & strength Increase body mass Enhances strength

FDA Statement of Identity

Sports Supplement

See for yourself

Mass Stack Extreme by Mass Genetics label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Mass Stack Extreme by Mass Genetics

These are the 4 active ingredients this product is made of. Select any to open its full monograph.

Serving size2 Capsule(s) Dosage formCapsule Servings per container30 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Ostarine

Interacts with
611 drugs
60 mg per serving

Ostarine (also called MK-2866 or enobosarm) is an experimental, unapproved drug known as a SARM (selective androgen receptor modulator), not a true di...

Ostarine monograph & interactions

Ligandrol

Interacts with
370 drugs
30 mg per serving

Ligandrol (LGD-4033) is a synthetic selective androgen receptor modulator (SARM), not a natural herb or approved dietary supplement. It is not approve...

Ligandrol monograph & interactions

Arimistane

Interacts with
4 drugs
30 mg per serving

Arimistane (sometimes sold as Estrovade) is a synthetic aromatase inhibitor marketed as a dietary supplement to lower estrogen and raise testosterone,...

Arimistane monograph & interactions

Laxogenin

No known
interactions
50 mg per serving

Laxogenin is a plant-based steroid-like compound marketed mostly to bodybuilders for muscle growth and recovery, but there is very little human resear...

Laxogenin monograph & interactions
Interaction report

Mass Stack Extreme by Mass Genetics Drug Interactions

Want to check YOUR meds against Mass Stack Extreme?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
614Drugs
444 Moderate 170 Minor

Ingredients driving the most interactions

Ostarine 611
Ligandrol 370

Each ingredient & the kinds of drugs it affects

For each ingredient in Mass Stack Extreme with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Ostarine6 drug types · 611 drugs

Cytochrome P450 3A4 (Cyp3A4) Inducers

Theoretically, concomitant use of ostarine with CYP3A4 inducers could decrease the clinical effects of ostarine.
Ostarine is partially metabolized by CYP3A4. Clinical research shows that taking rifampin, a potent inducer of CYP3A4, reduces the maximum plasma concentration of ostarine by 23% and the area under the curve by 43%.

Likelihood Possible Evidence B
Hepatotoxic Drugs

Theoretically, concomitant use with hepatotoxic drugs might increase the risk of adverse hepatotoxic effects.
Some clinical research shows that ostarine can increase alanine aminotransferase, a marker of liver damage, in some patients. Additionally, the U.S. Food and Drug Administration warns that supplements containing SARMs, such as ostarine, have been associated with reports of liver toxicity and there are at least two reports of drug-induced liver injury attributed to the use of ostarine.

Likelihood Possible Evidence D
Probenecid (Benemid)

Theoretically, concomitant use of ostarine with probenecid could increase the effects and adverse effects of ostarine.
Clinical research shows that probenecid increases ostarine levels and slows the clearance of ostarine, likely via inhibition of UDP-glucuronosyltransferase (UGT). Ostarine is partially metabolized by UGT.

Likelihood Possible Evidence B
Rifampin (Rifadin)

Theoretically, concomitant use of ostarine with rifampin could decrease the clinical effects of ostarine.
Clinical research shows that taking rifampin with ostarine reduces the maximum plasma concentration of ostarine by 23% and the area under the curve by 43%. Ostarine is partially metabolized by cytochrome P450 3A4 (CYP3A4), and rifampin is a potent CYP3A4 inducer.

Likelihood Possible Evidence B
Cytochrome P450 2C9 (Cyp2C9) Substrates

Theoretically, ostarine might increase levels of drugs metabolized by CYP2C9, although clinical research suggests this is not clinically relevant.
Although in vitro research suggests that ostarine inhibits CYP2C9, more robust clinical research shows that ostarine does not significantly affect CYP2C9.

Likelihood Unlikely Evidence B
Cytochrome P450 3A4 (Cyp3A4) Inhibitors

Theoretically, concomitant use of ostarine with CYP3A4 inhibitors could increase the effects and adverse effects of ostarine, although this is unlikely to be clinically significant.
Ostarine is partially metabolized by CYP3A4. However, clinical research shows that taking itraconazole, a potent inhibitor of CYP3A4, had minimal effects on the levels of ostarine in the body.

Likelihood Unlikely Evidence B

Ligandrol1 drug type · 370 drugs

Hepatotoxic Drugs

Theoretically, concomitant use might have additive hepatotoxic effects.
In case reports, patients were diagnosed with liver injury thought to be related to the use of products containing ligandrol.

Likelihood Possible Evidence D

Arimistane1 drug type · 4 drugs

Aromatase Inhibitors

It is believed that Arimistane inhibits the aromatase enzyme, which may interact with other aromatase inhibitors. This interaction could potentially increase the risk of side effects associated with low estrogen levels or from additive side effects, such as an increased risk of liver toxicity. It is recommended to consult with a healthcare provider before combining Arimistane with other aromatase inhibitors to assess the potential risks and benefits.

Likelihood Probable Evidence C
The maker

Brand information

Manufacturer and brand details for Mass Stack Extreme, from the product label.

Mass Genetics

See all Mass Genetics products
Name
Mass Genetics
Pharmacist Counseling Corner

Mass Stack Extreme by Mass Genetics: Common Questions

Does Mass Stack Extreme by Mass Genetics interact with any medications?
Yes. Based on its ingredients, Mass Stack Extreme has a known interaction with 614 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Mass Stack Extreme contains 4 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Is this product approved by the FDA?
No. Ostarine and ligandrol are unapproved investigational drugs that the FDA has not approved for any use. Arimistane is also not FDA-approved. This product is sold as a dietary supplement, but the ingredients are not approved medicines.
Can I take this if I'm pregnant or breastfeeding?
No. Ostarine and ligandrol are hormone-affecting drugs that must be avoided in pregnancy, and arimistane lowers estrogen, which could harm a developing baby. There is no safety data for any of these ingredients in pregnancy or breastfeeding — do not use.
What are the most common side effects?
With ostarine, the most common are abdominal pain, loss of appetite, constipation, diarrhea, and nausea. A number of users have also had rises in liver enzymes (ALT), a sign of liver stress. Ligandrol has been tied to liver injury and drops in good cholesterol. Arimistane and laxogenin have little documented side-effect data in humans.
Does this product actually work for muscle building?
The evidence is not established in the data we hold. All three major ingredients — ostarine, ligandrol, and arimistane — are rated as having insufficient reliable evidence for athletic performance, muscle strength, or related uses.
What is arimistane and why is it in this product?
Arimistane is believed to work as an aromatase inhibitor, meaning it blocks an enzyme involved in estrogen production. It's included because some people think lowering estrogen may support muscle building, but human safety and effectiveness data are very limited.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Mass Stack Extreme is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Mass Stack Extreme label
Sources

Sources & How We Checked

Mass Stack Extreme's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 23 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Ostarine 10 references
  1. Warning Letter: Ironmag Labs 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm582464.htm Accessed: November 1, 2017
  2. Warning Letter: Panther Sports Nutrition 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm581630.htm. Accessed: November 1, 2017
  3. Warning Letter: Infantry Labs LLC 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm582685.htm. Accessed: November 1, 2017
  4. Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 2013;14(4):335-45. PubMed
  5. Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II tri
  6. Coss CC, Jones A, Dalton JT. Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024 (enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin. Invest New Drugs 2016;34(4):458-67. PubMed
  7. FDA. FDA Warns against using SARMs in body building products. October 2017. Available at: https://www.fda.gov/newsevents/newsroom/fdainbrief/ucm583021.htm.
  8. Bedi H, Hammond C, Sanders D, Yang HM, Yoshida EM. Drug-induced liver injury from enobosarm (ostarine), a selective androgen receptor modulator. ACG Case Rep J 2021;8(1):e00518. PubMed
  9. Kintz P, Gheddar L, Paradis C, et al. Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR- d) and Selective Androgen Receptor Modulator (SARM) Abuse: Clinical, Analytical and Biological Data in a Case Involving a Poisonous Combination of GW1516
  10. Weinblatt D, Roy S. Drug-Induced Liver Injury Secondary to Enobosarm: A Selective Androgen Receptor Modulator. J Med Cases 2022;13(5):244-248. PubMed

See these in context on the Ostarine monograph →

Ligandrol 9 references
  1. Joseph JF, Parr MK. Synthetic androgens as designer supplements. Curr Neuropharmacol. 2015;13(1):89-100. PubMed
  2. Warning Letter: Ironmag Labs 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm582464.htm Accessed: November 1, 2017
  3. Warning Letter: Panther Sports Nutrition 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm581630.htm. Accessed: November 1, 2017
  4. Warning Letter: Infantry Labs LLC 10/23/17. FDA Inspections, Compliance, Enforcement, and Criminal Investigations, October 23, 2017. https://www.fda.gov/iceci/enforcementactions/warningletters/2017/ucm582685.htm. Accessed: November 1, 2017
  5. Barbara M, Dhingra S, Mindikoglu AL. Drug-induced liver injury associated with alpha bolic (RAD-140) and alpha elite (RAD-140 and LGD-4033). ACG Case Rep J 2020;7(6):e00409. PubMed
  6. Barbara M, Dhingra S, Mindikoglu AL. Ligandrol (LGD-4033)-Induced Liver Injury. ACG Case Rep J 2020;7(6):e00370. PubMed
  7. Koller T, Vrbova P, Meciarova I, et al. Liver injury associated with the use of selective androgen receptor modulators and post-cycle therapy: Two case reports and literature review. World J Clin Cases 2021;9(16):4062-4071. PubMed
  8. Flores JE, Chitturi S, Walker S. Drug-induced liver injury by selective androgenic receptor modulators. Hepatol Commun. 2020;4(3):450-452. PubMed
  9. Basaria S, Collins L, Dillon EL, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci 2013;68(1):87-95. PubMed

See these in context on the Ligandrol monograph →

Arimistane 1 reference
  1. Joseph JF, Parr MK. Synthetic androgens as designer supplements. Curr Neuropharmacol. 2015;13(1):89-100. PubMed

See these in context on the Arimistane monograph →

Laxogenin 3 references
  1. Dietary Supplements for Exercise and Athletic Performance — NIH Office of Dietary Supplements Source
  2. Dietary Supplements: What You Need to Know — NIH Office of Dietary Supplements Source
  3. Using Dietary Supplements Wisely — NIH NCCIH Source

See these in context on the Laxogenin monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring